Navigation Links
Blocking key enzyme in cancer cells could lead to new therapy
Date:8/1/2013

Researchers from the University of Illinois at Chicago College of Medicine have identified a characteristic unique to cancer cells in an animal model of cancer -- and they believe it could be exploited as a target to develop new treatment strategies.

An enzyme that metabolizes the glucose needed for tumor growth is found in high concentrations in cancer cells, but in very few normal adult tissues. Deleting the gene for the enzyme stopped the growth of cancer in laboratory mice, with no associated adverse effects, reports Nissim Hay, UIC professor of biochemistry and molecular genetics, and his colleagues in the August 12 issue of Cancer Cell.

Targeting glucose metabolism for cancer therapy -- while avoiding adverse effects in other parts of the body -- has been a "questionable" strategy, Hay said. But he and his coworkers showed that the glucose-metabolism enzyme hexokinase-2 can be almost completely eliminated in adult mice without affecting normal metabolic functions or lifespan.

Hexokinase-2 is abundant in embryos but absent in most adult cells, where related enzymes take over its role in metabolism. One of the changes that mark a cell as cancerous is expression of the embryonic enzyme. Hay and his colleagues showed that the embryonic version is required for cancer cells to proliferate and grow, and that eliminating it halts tumor growth.

They developed a mouse strain in which they could silence or delete the HK2 gene in the adult animal, and they found that these mice could not develop or sustain lung or breast cancer tumors but were otherwise normal and healthy.

"We have deleted the HK2 gene systemically in these mice, and they have been living for more than two years now. Their lifespan is the same as normal mice," Hay said.

The researchers also looked at human lung and breast cancer cells in the lab, and found that if they eliminated all HK2, the cells stopped growing.

"We think that the process
'/>"/>

Contact: Sharon Parmet
sparmet@uic.edu
312-413-2695
University of Illinois at Chicago
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Mount Sinai Researchers Find that Blocking Sugar Intake May Reduce Cancer Risk or Progression in Obese and Diabetic People
2. Study shows additional role for abiraterone in blocking tumor growth in CRPC
3. Autism Speaks trailblazer study -- Blocking cell distress signals can ease autism symptoms
4. Evidence supports blocking immune response to enhance viral therapy against solid tumors
5. Researchers prevent cancer spread by blocking tissue scarring
6. Spread of Cancer May be Reduced by Maximizing Melatonin by Blocking Blue Light Says Photonic Developments LLC
7. Moffitt researchers say effective immunotherapy for melanoma hinges on blocking suppressive factors
8. Patients with aberrations in two genes respond better to drugs blocking a well-known cancer pathway
9. Targeting errant immune system enzyme kills myelodysplastic cells
10. Molecular imaging enlists prostate enzyme to detect metastases
11. DNA-altering enzyme is essential for blood cell development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... VeloReality Inc. President Gary Bauer announced ... (RLVs) of world-famous velo courses for the company's VRide software ... popular indoor velo trainers. Two dozen additional Real Life Videos ... of November -- in time for the 2014 holiday ... in the VeloReality collection to over sixty. , The new ...
(Date:11/26/2014)... Il (PRWEB) November 27, 2014 ... excited to announce the kick-off of its annual ... encourages people to go to donate to those ... partner with local organizations to distribute the donations ... 20th, participating AlignLife locations will be accepting donations ...
(Date:11/26/2014)... Recently, Locks-Magnetic.com, a Chinese outstanding Maglocks ... magnetic locks on the Internet. It also provides a ... , As a leading company in the electronic ... customers to buy high quality locks. It can meet ... locks that are not only useful but also affordable. ...
(Date:11/26/2014)... Pharmaceutical and biotech companies require precise control ... and research activities, a task in which HVAC ... key role. Changes in temperature can promote the ... affect the quality of drugs and also support ... to address these problems and keeps the product ...
(Date:11/26/2014)... Alex Kramer HealthDay Reporter ... with rheumatoid arthritis may be more likely to achieve remission ... research. The study found that those who were heaviest ... underweight also lowered the odds of remission. "Medication for ... said Dr. Susan Goodman, the study,s lead author and a ...
Breaking Medicine News(10 mins):Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 2Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 3Health News:Fresh Products Launched by Famous Company Lock-Magnetic.com 2Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Cleanroom Technology Market to Hit $3,761.9 Million by 2019 - New Research Report by MarketsandMarkets 5Health News:Weight Could Influence Rheumatoid Arthritis Relief 2Health News:Weight Could Influence Rheumatoid Arthritis Relief 3
... People with bipolar,disorder and depression can find hope ... Health Care Decision Support system, available,through the Web site ... resources to support health decisions including:, -- ... depression;, -- links to online and ...
... Federal ... Regulation, ... the availability of DRA Tool(TM), a new feature of its,Sentinel RCM(TM) ... editing module that comprehensively supports the,additional reporting requirements of Section 6002 ...
... will showcase an,experimental model of a walking assist device ... with weakened leg muscles, at the,International Trade Fair on ... Disabled (BARRIER FREE 2008) which will be held at ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU095A ), Designed for people ...
... but nursing home study says risk greatest week after meds ... home patients who take antipsychotic drugs are 60 percent more ... who don,t take the drugs, a new study shows. , ... start taking the medications and gradually decreases, say Dutch researchers. ...
... surgeries has declined, so has death rate, study ... that perform fewer cardiac bypass operations don,t have more ... greater number of bypasses, a new study says. , ... hospitals that do more cardiac bypass operations have better ...
... for,Innovative Technology (CIT) today announced that CIT GAP ... Regeneration, LLC (STR), a medical,device company based in ... regeneration. CIT will invest $100,000., Joseph W. ... and counsel will help us begin developing the ...
Cached Medicine News:Health News:HAP Offers Web-Based Support for Depression and Bipolar Disorder 2Health News:HAP Offers Web-Based Support for Depression and Bipolar Disorder 3Health News:Sentry Data Systems Announces Deficit Reduction Act Compliance Tool 2Health News:Honda to Showcase Experimental Walking Assist Device 2Health News:Antipsychotic Drugs Linked to Pneumonia in Elderly 2Health News:Quality Care, Not Number of Procedures, Determines Bypass Results 2Health News:Quality Care, Not Number of Procedures, Determines Bypass Results 3Health News:CIT GAP Funds Invests in STR, LLC 2
(Date:11/26/2014)... , Nov. 25, 2014  Array ... today announced that its Chief Executive Officer, ... the following upcoming conferences.  The public is ... webcasts on the Array BioPharma website:  ... 3, 2014Time:1:30 p.m.  Eastern Time Location: Palace ...
(Date:11/26/2014)... Calif. and LONDON , Nov. ... and AstraZeneca (NYSE: AZN ) today announced that ... two doses of brodalumab in more than 1,800 patients with ... both Stelara ® (ustekinumab) and placebo at week 12. ... weight-based analysis group were each shown to be superior to ...
(Date:11/26/2014)... YORK and HERZLIYA PITUACH, Israel, Nov. 25, ... "Immune" or "the Company"), a clinical stage biopharmaceutical ... of targeted therapeutics for the treatment of inflammatory ... its previously announced underwritten public offering of 3,450,000 ... of the Company,s common stock, par value $0.0001 ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of ... financial results for its third quarter ended September 30, ... September 30, 2011 were $102,238 as compared to $34,446 ... nine months ended September 30, 2011, revenues were $257,609, ...
... Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, ... Senior Vice President and Chief Medical Officer. ... experience in the medical field.  He comes most recently ... and Medical Director of Global Businesses since 2005. In ...
Cached Medicine Technology:Radient Pharmaceuticals Announces FY 2011 Third Quarter Results 2Radient Pharmaceuticals Announces FY 2011 Third Quarter Results 3Prometheus Announces New Chief Medical Officer 2
... All of DOA Panel Test ... step in vitro test. It ... drug substances in human urine ... evaluated in the point of ...
... This device is a qualitative ... to inspect the,overdose usage of ... a metabolite of,cocaine, in human ... of 300 ng/mL. It is ...
The RapidBARBITURATE test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of barbiturates and in human urine specimens above a cut-off level of 3...
... AcT diff2 delivers performance, ... office labs and smaller laboratories. ... that offers a small sample ... closed analysis modes, a wide ...
Medicine Products: